Celldex Therapeutics (CLDX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
25 Jun, 2026Opening remarks and agenda
Meeting held virtually, with reminders about forward-looking statements and SEC regulations.
Introduction of board members, auditors, and key executives in attendance.
Confirmation that only four proposals, as outlined in the proxy statement, would be considered.
Quorum established with over 65 million shares represented.
Board and executive committee updates
All current directors nominated for re-election, with motions and seconds for each proposal.
Shareholder proposals
Four proposals presented: election of directors, ratification of auditors, amendment to equity plan, and advisory vote on executive compensation.
No additional shareholder proposals were submitted in advance.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Celldex Therapeutics
- Barzolvolimab failed to improve prurigo nodularis but remains safe; focus shifts to urticaria.CLDX
Study result22 Jul 2026 - Barzolvolimab showed rapid, significant disease control in CIndU and is advancing to Phase 3.CLDX
Status Update9 Jul 2026 - Phase 2 and 52-week data in CSU and CIndU drive phase 3 launches and broad clinical expansion.CLDX
Guggenheim Securities Inaugural Healthcare Innovation Conference8 Jul 2026 - Barzolvolimab delivers rapid, durable efficacy in CSU and ColdU, with strong financial backing.CLDX
Corporate presentation29 May 2026 - Q1 2026 net loss rose 46% to $78.7M; $345M raised to fund operations through 2028.CLDX
Q1 20267 May 2026 - Board recommends all proposals, with strong focus on pay-for-performance and ESG initiatives.CLDX
Proxy filing29 Apr 2026 - Key data for PN, CSU, and AD expected in 2024, with commercial and pipeline advances underway.CLDX
TD Cowen 46th Annual Health Care Conference29 Apr 2026 - Barzolvolimab shows strong, durable efficacy in urticaria with pivotal phase III data due Q4.CLDX
H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference14 Apr 2026 - Barzolvolimab demonstrates strong efficacy in urticaria, with major data readouts expected in 2024.CLDX
Leerink Global Healthcare Conference 202610 Mar 2026